Supernus Pharmaceuticals Files 8-K/A Amendment

TL;DR

Supernus filed an amendment to its July 31, 2025 report, mostly administrative stuff.

AI Summary

Supernus Pharmaceuticals, Inc. filed an 8-K/A on October 16, 2025, to amend its previous filing related to the period ending July 31, 2025. The amendment concerns financial statements and exhibits, but no specific new financial details or material events are disclosed in the provided excerpt.

Why It Matters

This filing indicates an update or correction to a previous report, suggesting ongoing administrative or disclosure processes for Supernus Pharmaceuticals.

Risk Assessment

Risk Level: low — The filing is an amendment to a previous report and does not introduce new material risks or events.

Key Players & Entities

• Supernus Pharmaceuticals, Inc. (company) — Registrant
• July 31, 2025 (date) — Reporting period
• October 16, 2025 (date) — Filing date

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value per share SUPN The Nasdaq Sto
• $0.0001 — ares of common stock of Sage, par value $0.0001 per share (the "Shares"), at a price of
• $8.50 — share (the "Shares"), at a price of (i) $8.50 per Share, in cash, less any applicable
• $3.50 — to receive contingent payments of up to $3.50 per Share, in cash, less any applicable

Filing Documents

• supn-20250731.htm (8-K/A) — 35KB
• pwc8-kconsent.htm (EX-23.1) — 3KB
• ex994unauditedproformastat.htm (EX-99.4) — 396KB
• 0001356576-25-000062.txt ( ) — 582KB
• supn-20250731.xsd (EX-101.SCH) — 2KB
• supn-20250731_lab.xml (EX-101.LAB) — 21KB
• supn-20250731_pre.xml (EX-101.PRE) — 12KB
• supn-20250731_htm.xml (XML) — 3KB

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (a) Financial Statements of Business Acquired The Audited Annual Financial Statements of Sage Therapeutics, Inc. as of and for the fiscal years ended 2023 and 2024 are filed as Exhibit 99.2 to this amendment, and incorporated herein by reference. The Unaudited Interim Financial Statements of Sage Therapeutics, Inc. as of and for the three and six months ended June 30, 2024 and 2025 are filed as Exhibit 99.3 to this amendment, and incorporated herein by reference. (b) Pro Forma Condensed Combined Financial Information The Unaudited Pro Forma Condensed Combined Balance Sheet as of June 30, 2025, Unaudited Pro Forma Condensed Combined Statement of Operations for the six months ended June 30, 2025 and Unaudited Pro 2 Forma Condensed Combined Statement of Operations for the year ended December 31, 2024 filed as Exhibit 99.4 to this amendment and incorporated herein by reference. (c) Exhibits Exhibit 23.1 - Consent of PricewaterhouseCoopers LLP dated October 16, 2025. Exhibit 99.2 - Audited Annual Financial Statements of Sage Therapeutics, Inc. as of and for the fiscal years ended 2023 and 2024 (incorporated by reference from Item 9A, and pages 120 and F-1 through F-40 of the Sage Therapeutics Annual Report on Form 10-K filed by Sage Therapeutics, Inc. on February 11, 2025). Exhibit 99.3 - Unaudited Interim Financial Statements of Sage Therapeutics, Inc. as of and for the three and six months ended June 30, 2024 and 2025 (incorporated by reference from pages 7 through 37 of the Sage Therapeutics Quarterly Report on Form 10-Q filed by Sage Therapeutics, Inc. on July 30, 2025). Exhibit 99.4 — Unaudited Pro Forma Condensed Combined Balance Sheet as of June 30, 2025, Unaudited Pro Forma Condensed Combined Statement of Operations for the six months ended June 30, 2025 and Unaudited Pro Forma Condensed Combined Statement of Operations for the year ended December 31, 2024. Exhibit 104 — The cover page from thi

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SUPERNUS PHARMACEUTICALS, INC. DATED: October 16, 2025 By: /s/ Timothy C. Dec Timothy C. Dec Senior Vice-President and Chief Financial Officer 4